Tennessee Retina   Report issue

Academic/Hospital Phase 4
Founded: Nashville TN United States (1978)

Organization Overview

First Clinical Trial
2007
NCT00533520
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Brandon G. Busbee, MD | Tennessee Retina | Tennessee Retina, P.C,.

Active Ingredients

Drugs in Phase 4 Trials (2)

aflibercept (zaltrap) (3 trials)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroidal Neovascularization (Phase 4)

Dissociative Disorders (Phase 4)

Macular Degeneration (Phase 4)

Macular Edema (Phase 4)

Neovascularization, Pathologic (Phase 4)

Retinal Detachment (Phase 4)

Retinal Vein Occlusion (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 2